Interview with Sophie Kornowski-Bonnet, President, France, Roche France
Roche has a long history in France and currently enjoys a higher position than its worldwide ranking. Can you elaborate on the importance of this market for the group overall?…
Address: 52, avenue du Parc, Neuilly sur Seine 92521,France
Tel: +33 (0)1 46 40 50 00
Web: http://www.roche.fr/portal/roche-fr/index_
Leading at the hospital, Roche is the 3rd largest pharmaceutical companies in France in 2008.
The Roche Group is present in France through two entities:
• Roche SAS, specializes in prescription drugs
• Roche Diagnostics, the French biological diagnostics
• Total turnover: € 1 654.2 million
• New investments: 30.5 million €
• R & D Spending: 26.1 M €
• Total staff: 1 767 people
Roche offers patients and the medical prescription drugs in particular therapeutic areas of Cancer
Anemia
Transplantation
Virology
Rheumatology
Autoimmune Diseases
Metabolism Disorders
Roche has a long history in France and currently enjoys a higher position than its worldwide ranking. Can you elaborate on the importance of this market for the group overall?…
The President of Fefis, and the recently elected President of Medicen Paris Region, a Paris-based business cluster, talks about the need to build the future of the French health economy, not…
The director of GEMME reveals how the French generics market is young in comparison to other European countries – where generics were on the market twenty years before they became…
The Chairman & CEO of DBV Technologies reveals how they have developed a new therapeutic method and new technology in the form of a patch to treat various allergies. DBV received…
The President of Cristers discusses the history of generic drugs in France and what steps can be taken to increase generics penetration, while also outlining the ‘cooperative’ business model behind…
Yves Bur reveals how the motivation behind his political engagement has been to raise awareness around the importance of improving the social security system. Bur also explains why having a…
The General Manager of LEEM talks about the association’s strategy based on three key points, innovation, attractiveness and efficiency; how the Mediator affair has placed a question mark on the…
CPhI Worldwide 2014, held this year in Paris, was the largest ever event held by the organizers, with more than 36,000 attendees and 2,500 exhibitors. PharmaBoardroom was a media partner…
Nycomed lost an important patent with Pantoprazole in the middle of 2009, which has undoubtedly warranted some restructuring. What has been the impact of this loss on business in France,…
BMS recently announced divesting from their facilities in Epernon and Meymac but at the same time reinforcing manufacturing in Agen. Could you speak to strategy of this restructuring within France…
You worked for many years in emerging markets, especially in Latin America, but also in neighbor countries such as Spain. How these previous experiences in very different markets can now…
In the wake of the most recent CSIS meeting, LFB and Sanofi-Aventis announced the intention to collaborate in bioproduction. What are the terms to this agreement and what are the…
We have had the chance to interview a number of Teva’s subsidiaries in Europe, and witnessed how each of them has dealt with the strong transformations that the group has…
See our Cookie Privacy Policy Here